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Abstract
A series of 3,6-disubstituted β-carbolines was synthesized and evaluated for their in vitro affinities
at αxβ3γ2 GABAA/benzodiazepine receptor subtypes by radioligand binding assays in search of α1
subtype selective ligands to treat alcohol abuse. Analogues of β-carboline-3-carboxylate-t-butyl ester
(βCCt, 1) were synthesized via a CDI-mediated process and the related 6-substituted β-carboline-3-
carboxylates 6 including WYS8 (7) were synthesized via a Sonogashira or Stille coupling processes
from 6-iodo βCCt (5). The bivalent ligands of βCCt (32 and 33) were also designed and prepared
via a palladium-catalyzed homocoupling process to expand the structure-activity relationships (SAR)
to larger ligands. Based on the pharmacophore/receptor model, a preliminary SAR study on 34
analogues illustrated that large substituents at position -6 of the β-carbolines were well tolerated. As
expected, these groups are proposed to project into the extracellular domain (LDi region) of
GABAA/Bz receptors (see 32 and 33). Moreover, substituents located at position -3 of the β-carboline
nucleus exhibited a conserved stereo interaction in lipophilic pocket L1, while N(2) presumably
underwent a hydrogen bonding interaction with H1. Three novel β-carboline ligands (βCCt, 3PBC
and WYS8), which preferentially bound to α1 BzR subtypes permitted a comparison of the
pharmacological efficacies with a range of classical BzR antagonists (flumazenil, ZK93426) from
several different structural groups and indicated these β-carbolines were “near GABA neutral
antagonists”. Based on the SAR, the most potent (in vitro) α1 selective ligand was the 6-substituted
acetylenyl βCCt (WYS8, 7). Earlier both βCCt and 3PBC had been shown to reduce alcohol self-
administration in alcohol preferring (P) and high alcohol drinking (HAD) rats but had little or no
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Alcohol addiction and dependence remain significant public health concerns, impacting
physical and mental well-being, family structure and occupational stability.4 While advances
have been made in the development of novel therapies to treat alcoholism,5–8 alcohol-
dependent individuals represent a heterogeneous group,9–11 and it is unlikely that a single
pharmacological treatment will be effective for all alcoholics. Hence, a better understanding
of the neuromechanisms which regulate alcohol seeking behaviors and the design of clinically
safe and effective drugs that reduce alcohol addiction and dependence remain a high priority.
7,12 While the precise neuromechanisms regulating alcohol-seeking behaviors remain
unknown, there is now compelling evidence that the GABAA receptors within the
striatopallidal and extended amygdala system are involved in the “acute” reinforcing actions
of alcohol.13–18 Among the potential GABAA receptor isoforms within the VP regulating
alcohol-seeking behaviors, GABA receptors containing the α1 receptor subtype (GABA α1)
appear preeminent. Thus, Criswell and colleagues observed that acute alcohol administration
selectively enhanced the effects of ionotophoretically applied GABA in the ventral pallidum
(VP).19,20 However, no effects were seen in the septum, ventral tegmental area (VTA), and
CA1 hippocampus. These data suggest the α1 Bz/Gaba(A)ergic receptor plays an important
role in alcohol-motivated behaviors. Research on the neuroanatomical basis of alcohol reward
has shown that the NACC, VTA, VP, central amygdala (CeA), and hippocampus are all
involved in GABAergic regulation of ethanol (EtOH) reinforcement.2,21–24 Other
investigators have identified a dense reciprocal projection from the VP to the NACC,25–27 and
many of these have been found to be GABAergic neurons.28–30 The NACC is now well
established as a substrate that regulates the reinforcing properties of abused drugs.13 Finally,
immunohistochemical31,32 and in situ hybridization studies33–35 have demonstrated that the
VP contains one of the highest concentrations of mRNA encoding the α1 subunit in the CNS.
These findings, together with pharmacological studies suggesting the VP plays a role in reward-
mediated behaviors of psychostimulants and opiates,28,36–39 suggest a possible role of the VP-
α1 receptors in the euphoric properties of alcohol. Findings of previous studies concluded that
inhibition of VP-α1 receptors by the α1 preferring antagonist 3-PBC produced marked
reductions on alcohol-maintained responding.9,15,40,41 The α1-mediated suppression at the VP
level by 3-PBC showed a high degree of neuroanatomical specificity. Specifically, the α1-
mediated suppression was not observed with the more dorsal placements in the NACC or
caudate putamen. The failure of 3-PBC to alter alcohol self-administration in the NACC/
striatum is in agreement with previous research which has consistently reported a lack of
expression of the α1 transcript in the NACC caudate.31–35
An understanding of the neuromechanisms that regulate alcohol drinking is key in the
development of drugs to treat alcohol addiction and dependence in humans.2 In recent years,
much evidence has accumulated in favor of the GABA system;22,23,42,43 however much
remains unknown about the role of specific GABAA receptor subtypes in regulating ethanol
reinforcement. This is due to both a lack of high-affinity and selective ligands capable of
discriminating among the GABAA receptor subunits and the heterogeneity of various subunits
within the known alcohol reward circuitry.31,34 Of the potential GABAA receptors involved
in the reinforcing properties of alcohol, evidence suggests the α1 subtype within the VP may
play an important role in regulating alcohol-seeking behaviors, as mentioned above. The VP
contains one of the highest distributions of α1 subunits in the mesolimbic system.32–35 Finally,
acute ethanol administration has been reported to selectively enhance the effects of
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iontophoretically applied GABA in the VP. These effects correlate highly with [3H] zolpidem
binding (an α1-subtype selective agonist).19,20
The GABAA receptor is the major inhibitory neurotransmitter receptor of the central nervous
system (CNS) and the site of action of a variety of pharmacologically and clinically important
drugs, such as benzodiazepines, barbiturates, neuroactive steroids, anesthetics and convulsants.
44 It is now clear that these receptors regulate the excitability of the brain, anxiety, muscle tone,
circadian rhythms, sleep, vigilance, memory, and learning.44 There are several disease states
thought to be associated with the improper functioning of this system, including anxiety,
epilepsy,45 insomnia,46 depression and bipolar disorder,47,48 schizophrenia,49 as well as mild
cognitive impairment and Alzheimer’s disease.50 A role of GABAA receptors in drug and
alcohol abuse has also been reported.51–53 Briefly, GABAA receptors are composed of 5
subunits that form a central chloride channel and can belong to different subunit classes. A
total of 19 subunits (6α, 3β, 3γ, 1ε, 1π, 1θ, 3ρ) of the GABAA receptor have been cloned and
sequenced from the mammalian nervous system.54–59 All these polypeptides possess an
approximate molecular mass of ~ 50 kD and are structurally related.
To evaluate the role of the α1 receptor in regulating alcohol reinforcement, 3-propoxy-β-
carboline hydrochloride (3-PBC), a mixed benzodiazepine (BDZ) agonist-antagonist with
binding selectivity at the α1 receptor was developed.2 Compared with the prototypical BDZ
agonist zolpidem, 3-PBC exhibited a slightly higher binding selectivity for the α1 receptor.
60,61 Preliminary behavioral studies in several species (e.g., rats, mice, and primates) show that
3-PBC is a BDZ antagonist, exhibiting competitive binding-site interactions with BDZ agonists
at low to moderate doses (2.5–15 mg/kg).60,62,63 At higher doses (15–60 mg/kg), 3-PBC
produces anxiolytic effects in the plus maze that are comparable with those of chlordiazepoxide
in alcohol preferring (P) rats.62–65 Thus given the proposed subunit composition of the GABA
receptors within the CeA,31,32,34,66 pharmacological compounds capable of exploiting the α1,
α2, and α3 subunit-containing GABAA receptors represent optimal tools to evaluate the role
of the GABAA receptors in alcohol reinforcement and better understand neurobehavior and
ethanol responding.
α1 Subtype Selective Ligands
The β-carboline-3-carboxylate-t-butyl ester (βCCt) is a mixed benzodiazepine agonist-
antagonist ligand with binding selectivity at α1 receptors;2,62,67 βCCt also exhibits some
affinity (albeit lower) for both α2 and α3 receptors. Behavioural studies in several species (eg,
rats, mice, primates) show that βCCt is a BDZ antagonist exhibiting competitive binding site
interaction with BDZ agonists over a broad range of doses.60,62,68–72 Other studies show that
βCCt produces anxiolytic effects in rodents62 and potentiates the anticonflict response induced
by α1 subtype agonists in primates.70 Thus, βCCt displays a weak agonist or antagonist profile
depending on the behavioral task, species, and dose employed.
In studies involving the α1 subtype, βCCT and 3-PBC were observed to selectively reduce
alcohol-motivated behaviors in a variety of experiments.2,73 However, unlike the α5 selective
inverse agonist RY-23, both the β-carboline antagonists βCCT and 3-PBC displayed mixed
weak agonist-antagonist profiles in vivo in alcohol P and HAD rats. Therefore, in addition to
being able to study the molecular basis of alcohol reinforcement, α1 Bz β-carboline ligands
which display mixed agonist-antagonist pharmacology in alcohol P and HAD rats may be
capable of reducing alcohol intake while eliminating or greatly reducing the anxiety associated
with habitual alcohol, abstinence or detoxification. Thus, these types of ligands may be ideal
clinical agents for the treatment of alcohol dependent individuals.2,73
Consequently, several series of structurally different compounds have been synthesized which
possess some α1 subtype selectivity.67,74–77 The discovery of high affinity, saturable, and
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stereospecific ligands for the BzR has been coupled with the demonstration that β-carbolines
exhibited an affinity for the BzR.78–85 Some of these agents act on the BzR to induce effects
that are functionally opposite (inverse agonists/antagonists) to those of classical BDZs.
Consequently, the affinities of a wide variety of β-carbolines have been reported on
synaptosomal membranes from this laboratory,60,72,78,80,81,86–90 and the laboratories of
others,91–96 and this prompted the study of the binding affinities of a series of β-
carbolines67 at 5 recombinant GABAA/BzR subtypes (α1β3γ2, α2β3γ2, α3β3γ2, α5β3γ2 and
α6β3γ2) expressed from recombinant human cell lines.91,97 In general, this series of β-carboline
ligands exhibited some selectivity at α1 receptor subtypes including βCCt (1) and 3-PBC (2).
2,3 These two ligands displayed a 20-fold and 10-fold selectivity, respectively, for the α1
subtype over the α2 and α3 receptors, as well as over 150-fold selectivity for the α1 site over
the α5 subtype.2,3 βCCt (1) was more selective at the α1 subtype in vitro than the classical α1
selective agonists zolpidem (3) and CL 218872 (4) (Figure 1).60,98,99 A number of in vitro and
in vivo studies employing α1 (e.g., zolpidem, CL 218872,68 βCCt, and 3-PBC3) selective
ligands suggest the α1-containing GABAA/Bz receptors of the ventral pallidum (VP) play an
important role in regulating alcohol’s neurobehavioral effects; particularly alcohol’s
reinforcing properties as mentioned above.2,3,19,20,35
Structure Activity Relationships
A predictive 3-D QSAR pharmacophore/receptor model for inverse agonist/antagonist β-
carbolines was initially developed via Comparative Molecular Field Analysis (CoMFA) and
later refined.100,101 Affinities of ligands from 15 different structural classes have been
evaluated.61 Based on this CoMFA study of a series of β-carbolines, Huang et al. reported that
β-carbolines bind to all diazepam sensitive (DS) sites of the BzR with some selectivity at the
α1 containing receptor isoform and this was confirmed by in vitro binding affinity of these
ligands.102 A lipophilic region (LDi) of the pharmacophore receptor model appears to be larger
in the α1, α2 and α3-containing receptor isoforms and important for α1 subtype selectivity.61
More recently, during the design and synthesis of βCCt-related bivalent ligands,103–106 it was
found that a series of 3,6-disubstituted β-carbolines (see Figure 1), including 6-iodo-βCCt (5)
and 6-trimethylsilanyl-ethynyl-βCCt (6) (Figure 1) possessed α1 subtype selectivity.103
The rigidly linked linear bivalent ligands of βCCt at position “6” did bind to BzR receptors
with some α1 subtype selectivity and may provide the desired α1 selectivity through specific
occupation of the LDi region of the pharmacophore/receptor model.103 Although the two 3,6-
disubstituted-β-carbolines 5 and 6 are less potent than βCCt (1), the potent binding affinities
observed for 5 and 6 at the α1 subtype has stimulated the synthesis of the βCCt analogs: 3-
substituted-β-carbolines as well as 3,6-disubstituted-β-carbolines.
On the other hand, these studies also indicated that the selectivity of GABAA/BzR site ligands
could be described in relation to binding and pharmacological efficacy in vitro. This efficacy
was based on the capacity of a ligand to modulate GABAergic function.54 BzR ligands act to
modulate chloride flux over a continuum ranging from positive to negative modulation, with
neutral antagonists acting theoretically, at a point on the continuum, with zero intrinsic efficacy
(e.g. they bind to the receptor but exhibit no activity).74 Consequently, the pharmacological
profiles of βCCt and 3-PBC at recombinant α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and
α6β3γ2 receptor subtypes expressed in Xenopus oocytes were investigated.2,3,64
The results of this study illustrated that βCCt was a near “neutral” antagonist (i.e., little or no
efficacy) at all receptor subtypes. In fact, the level of intrinsic efficacy of βCCt in oocytes was
less at some receptor subtypes than the classical nonselective antagonist flumazenil (Ro
15-1788, for which intrinsic efficacy at all BZ-sensitive GABAA subtype was relatively low,
but not zero). To date, no compound has been characterized that exhibits zero efficacy at all
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BzR subtypes, raising the possibility that a compound labeled as an “antagonist” may indeed
exhibit functional activity given the right circumstances. For example, more recently, the
efficacies of both βCCt and 3-PBC in the selective reduction of alcohol responding and
production of anxiolytic effects were demonstrated in P and HAD rats following oral
administration.107 When compared with naltrexone treatment, these reductions in alcohol
responding were more selective and longer in duration.107 In summary, the antagonist βCCt
exhibited either a neutral or low-efficacy agonist response at GABA receptors in oocytes.
Although there has been some debate in the literature at present as to whether a ligand’s binding
or efficacy selectivity was “the more salient factor” in determining a ligand’s capacity to
function as an alcohol antagonist,3,67,107 the knowledge of the efficacy of an individual putative
anti-alcohol reward ligand across all GABAA receptors was indeed critical to the knowledge
of their mode of action in the CNS.
Based on the limited availability of data on the series of α1 “binding” and “efficacy” selective
β-carbolines (βCCt, 3PBC) as anti-alcohol agents108 the present study was designed to expand
the SAR and search for better α1 subtype selective ligands. These compounds may be promising
modulators of alcohol-related co-morbid behaviors in alcohol dependence via the GABAA/
BzR system. Although recent evidence suggests a salient role for GABAergic mechanisms in
the regulation of excessive alcohol drinking and the negative affective states associated with
abstinence, decreased GABAergic tone stemming from chronic alcohol use and withdrawal
may serve to generate anxiety.109 Thus, compounds that enhance GABAergic tone may be
effective and safe treatments for both excessive alcohol drinking and the negative affective
states associated with abstinence and may represent novel pharmacotherapies to treat
alcoholism.
In this regard, the chemistry and pharmacological evaluation of a series of structurally modified
analogues of βCCt (1) as selective and potent α1 subtype-preferring ligands are described. The
synthesis of the α1 selective compound 7 (WYS8) and the structure-activity relationships
(SAR) of 3,6-disubstituted β-carbolines are also presented. The established pharmacophore/
receptor model61,110 of BDZ binding sites was employed to design ligands with respect to the
LDi region at position-6, as well as characterize the binding pocket L1 at position-3. Protein-
ligand docking of the α1 subtype GABAA receptor protein and WYS8 illustrated the agreement
between the pharmacophore/receptor model and BzR site prediction based on homology
modeling.110–113
Chemistry
The synthesis of the ligands under study is outlined in Schemes 1, 2 and 3. The important
precursor β-carboline-3-carboxylate-ethyl ester (βCCE, 8) and its corresponding acid (9) were
the intermediates required for large-scale synthesis of βCCt (1), as well as an intermediate
required for the synthesis of the new β-carbolines. As outlined in Scheme 1, D-L tryptophan
10 was converted into tetrahydro-β-carboline (11) via a Pictet-Spengler reaction on kilogram
scale. Fischer esterification of 11, followed by oxidation with activated MnO2 provided the
intermediate BCCE (8) on 200 gram scale. Hydrolysis of ester 8 to provide the acid 9, was then
followed by esterification in t-butanol with CDI to provide BCCt (1). The synthesis of
3PBC·HCl (1) was more difficult to scale up due to the complex last step (14→2). It began
with βCCE (8) from Scheme 1, which was heated with hydrazine to furnish hydrazide (13) in
82% yield. The hydrazide (13) was stirred with nitrous acid to provide an azide, which was
unstable, and was converted into 3-amino-β-carboline (14) when stirred with acetic acid
(Scheme 1) via a Curtius rearrangement. The last step, originally developed on a 100 mg scale,
has now been scaled up to 4 gram levels to furnish 3PBC hydrochloride salt in reasonable yield
for studies in primates.
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In Scheme 2, the β-carboline alkyl esters 16–20 as well as chiral βCCt analogs 21–24, and 25,
26 were prepared via the CDI-mediated process described above (see Scheme 1).113 Briefly,
when β-carboline-3-carboxylic acid 9 was treated with 1,1-carbonydiimidazole (CDI) in dry
DMF, the imidazole derivative 27 which resulted was subsequently transformed into the
desired esters by treating it with the corresponding alcohols (individually) in the presence of
DBU in a one-pot sequence. The key potential α1 chiral selective analogs CMD-30 R/S isomers
(21 & 22) can be synthesized by the CDI method in 90% yield (individually) on 10 gram scale.
The required starting chiral alcohols were obtained by asymmetric reduction of the
corresponding trifluoromethyl ketones with (+)-DIP-chloride.114,115 or the (−)-DIP-
enantiomer. The 6-substituted-iodo-β-carboline-3-carboxylates 28 were then prepared as
intermediates to generate different functionality at position-6 through a palladium-mediated
cross coupling process. For example, as illustrated in Scheme 2, βCCt (1) was treated with I2/
CF3COOAg in chloroform to provide 6-iodo-βCCt 5 (see also 28a) in 80% yield and the 6-
substituted targets 29–31 were obtained in 65%–83% yields via a Stille coupling process
employing commercially available substituted tributyl-stannanes. The substitution by halogen
occurred at position-6 as indicated by analysis of 5 (or 28a) by NMR spectroscopy especially
with One Dimensional Nuclear Overhauser Effect (NOE) experiments.
Depicted in Scheme 3 are the synthetic routes for the βCCt related bivalent ligands 32 and
33.103 In order to efficiently effect a palladium mediated Sonogashira process at position-6 of
β-carbolines (a reactive electron-rich indole heterocycle), protection/deprotection of the indole
Na-H group in β-carbolines 34 and 35 was necessary. The Boc protected 6-ethynyl-β-
carboline-3-carboxylic acid t-butyl ester (34) was prepared directly from 6-substituted
acetylenyl βCCt (7), which was initially termed WYS8. The common intermediate iodo-βCCt
5 (see also 28a) was then converted into the 6-substituted trimethylsilylacetylenyl βCCt (6)
via a Sonogashira coupling process.116,117 At this point, TBAF was employed to remove the
trimethylsilyl group to provide the 6-substituted acetylenyl βCCt analog WYS8 (7) as well.
The ester 7, was then protected with a Boc group at the N(1) position to afford 34 under standard
conditions. A Sonogashira process was then employed to couple 34 with Boc protected iodo-
βCCt (35) to provide the rigid two carbon linked bivalent ligand 32 of βCCt. The Boc protecting
group was removed thermally by heating in cumene at high dilution and bivalent ligand 32
was obtained. The bisacetylenic bridged ligand 33 was synthesized from the Boc protected 6-
ethynyl-βCCt 34 via a homocoupling process,118 followed by the removal of the Boc group
under thermal conditions in cumene at high dilution.
Results and Discussion
(1) βCCt bivalent ligands
The in vitro biological protocols employed in the present study follow the published
procedure119,120 and are detailed in the Experimental Section. Although the α1β3γ2 BzR/
GABAergic subtype is very similar in structure to the α2 and α3 subtypes, there are slight
differences.61,121 One major difference is in region LDi, which appears larger in the α1 subtype
than in either the α2, or α3 or α5 subtypes. This is located near position -6 of βCCt (1) and can
be seen in the model of the Comparative Molecular Field Analysis (CoMFA) study for the
α1 subtype (Figure 3).110,122 In particular, blue contours in the western region of the
pharmacophore/receptor model imply positive lipophilic interactions in this area that
corresponds to region LDi (a region in the pharmacophore adjacent to the extracellular domain
of the receptor) of the unified pharmacophore/receptor model. In this region, bulky substituents
are tolerated and occupation of this area with substituents appears to enhance affinity at α1
subtypes. This knowledge provided an opportunity to introduce a linker between two
pharmacophoric β-carboline-3-carboxylate residues in order to design selective and rigid
bivalent ligands. As described in the Introduction, initial efforts to find a novel series of α1-
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preferring ligands focused on design and synthesis of βCCt bivalent ligands. Although the
α1 subtype selectivity was not amplified with the particular acetylenyl linked bivalent ligand
32, the ligand does bind preferentially at α1 subtypes (Table 1). It was proposed the two-carbon
linker was not long enough and that crowding between the second βCCt unit and the receptor
protein decreased the binding affinity at the α1 subtype, thereby negating some of the potential
selectivity. However, these rigidly linked linear bivalent ligands 32 and 33 fit the GABAA/
BzR pharmacophore/receptor model very well (Figure 4).110 The unit at C-6, presumably,
protrudes into the extracellular domain of the BzR, as previously expected,102,103 and bound
to BzR with some α1 subtype selectivity.102,103 To our knowledge these are the first two
bivalent ligands in the β-carboline series, which bind to BzR. Further pharmacological
evaluation in vivo of the βCCt bivalent ligand with the longer rigid linker should shed light on
the above hypothesis and this would also provide some tools to determine the size and exact
location of the LDi region.
(2) WYS8
A series of 6-substituted-β-carboline-3-carboxylates have been synthesized and bound in
vitro to the α1β3γ2 BzR subtype preferentially as compared to other subtypes (see Tables 1–
3).61,102 These ligands have also been modeled in the GABAA/BzR pharmacophore model,
and the 6-substitutents align well in the LDi region.123 Occupation of this region should lead
to enhanced selectivity of a ligand at the α1 containing isoform. Among the new 3,6-
disubstituted-β-carbolines, 6-trimethylsilanylethnyl-βCCt 6 has been recently synthesized and
found in vitro to prefer the α1 subtype. However, the most selective ligand for the α1 subtype
was WYS8 (7). This α1 subtype selective ligand was 100 fold more selective over the other
subtypes. This was the most α1 subtype selective ligand reported, to date, to these authors’
knowledge. This 6-substituted acetylenyl βCCt 7 was 214 fold more selective for α1 isoforms
over α5 isoforms. Studies of SAR in Table 1 confirmed the occupation of region LDi of the
receptor pharmacophore model did enhance α1 selectivity in comparison to the affinity of the
non-selective ligand diazepam or the α5 selective ligand, RY080. As illustrated in the two
dimensional Figure 5, full occupation of the LDi lip β-carbolines may account for the potency/
selectivity of this class of ligands at the α1 subunit. Analysis of the in vitro binding data for
this series of bulky 6-substituted β-carbolines (Table 1) has shown some selectivity for the
α1 receptor subtype. In addition, it is important to note that binding affinity in this series of
ligands of greater than 400nM usually results in zero efficacy at the subtype at
pharmacologically relevant concentrations.
Homology models employed here of the GABAA receptor were as described previously111,
124 except that a number of alternative models were considered for loop C, which was two
residues shorter than the template and hence built from a loop database. The final model was
selected based on assessment of model quality125 and consistency with published mutational
data,126–130 particularly with the T207 side-chain appropriately positioned facing the
benzodiazepine-binding pocket. Positioning of WYS8 in the BzR was executed using a genetic
algorithm (FlexiDock®). Flexible docking provides a means of docking ligands into protein
active sites.
(3) 3-Substituted β-carbolines
It was initially believed by Braestrup, Loew, and others that an ester moiety at position-3 of
β-carbolines was required for a ligand to exhibit high affinity binding at Bz binding sites.84,
95,131,132 However, high affinity binding of β-carbolines including the antagonist 3-propoxy
β-carboline (3-PβC, Table 2b) demonstrated this was not the case.81,88,89 Examination of data
from additional studies78,88,89 have suggested that at least two factors affected high affinity
binding at BzR with respect to 3-alkoxy substituted β-carbolines,60,79,102,123 one of which was
the lipophilicity of the substituent which interacted at L1. The L1 pocket tolerates linear groups
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up to 4 carbons in length. Comparison of the in vitro receptor binding affinity of the ligands
depicted in Table 2b indicated the ethers 36 and 37 bind potently to α1 subtypes while 34 does
not; binding affinity is lost, illustrating that the substituent at the 3-position is to large to allow
the ligand to bind. Likewise, the 3-benzyloxy β-carboline 35 is also too bulky to fit the L1
pocket despite its lipophilic nature. The second factor was the ability of the substituent at
position-3 to release electron density to the pyridine ring. This enhanced the basicity of the
nitrogen atom at N(2) which resulted in a greater ligand-receptor interaction at H1. Analysis
of the binding affinities of the novel trifluoroalkyl esters of β-carboline-3-carboxylic acid
further supported this hypothesis (Table 2a). The trifluoroalkyl esters exhibited reduced
binding affinity at all receptor subtypes when compared to their corresponding alkyl esters
(20 vs. 19, 15 vs. βCCE). Since the trifluoromethyl was a strong electron-withdrawing group,
when compared to the corresponding alkoxycarbonyl moiety, the 3-trifluoroalkoxycarbonyl
substituent would decrease electron density to the pyridine (N2) ring reducing the basicity of
the nitrogen atom. This would result in a weaker ligand-receptor interaction at H1. In addition,
the trifluoroalkyl group was less lipophilic than the corresponding alkyl moiety, which may
result in a weaker interaction at L1. Ramachandran and Hanzawa have reported that
trifluoromethyl groups are nearly as large as isopropyl or t-butyl functions.114,133 It was
possible, the trifluoromethyl substituted ligands are simply too large to exert high affinity
binding; however, βCCT (1), WY-B-24 (25) and CM-A-77 (26) all bound with good potency
to α1 BzR subtypes (see Tables 1 and 2), and these ester functions occupy a large molecular
volume.
(4) Chiral 3-substituted β-carbolines
Examination of the binding data for the enantiomeric pair of β-carboline sec-butyl esters 23
and 24 (Table 3) indicated that the (R)-enantiomer 24 bound tighter to the receptor subtypes
than the (S) isomer 23. Although both enantiomers exhibited approximately a 4-fold selectivity
for the α1β3γ2 subtype, the (R) isomer remained more potent in vitro at all 5 BzR subtypes.
Because the receptor subtype selectivity remained about the same for the (R) and (S) isomers,
this indicated the stereoenvironment in lipophilic pocket L1 was highly conserved across the
entire series of BzR subtypes in agreement with earlier work on the binding affinities of the
enantiomers of the framework-constrained 4,5-substituted pyrroloimidazobenzodiazepines.
134 It is possible that lipophilc pocket L1 is simply a large area in the pharmacophore/receptor
model with only small steric differences between receptor subtypes. More work will be required
to determine if this is the case. A similar result was observed in the case of (R) and (S) isomers
of CMD-30. The (R)-enantiomer CMD-30 R (22) bound slightly tighter to the receptor subtype
than the (S) isomer (21) with almost 70 fold more selectivity for the α1 subtype over the α5
isoform. In addition, previously it was reported that a hydrogen bond between the N (9) H atom
of a β-carboline and the secondary site A2 in the receptor pharmacophore was required for
potent inverse agonist activity in vivo.78,79 Therefore, a series of ligands with the Boc
protection at position-9 such as 40 and 41 were evaluated and were not α1 subtype selective
ligands. In fact, they did not bind to BzR at all in agreement with previous work.123
(5) Efficacy of α1 Preferring Ligands in oocytes at GABAA Receptor Channels
The physiological efficacy of βCCt, as compared to other Bz antagonists, was investigated
across all diazepam sensitive (DS) receptor subunits at recombinant α1, α2, α3, and α5 receptor
subunits in the Xenopus oocytes assay and is depicted in Figure 2 by Harvey et al.2,64 In
comparison to other BzR antagonists such as flumazenil and ZK 93426, as mentioned, βCCt
exhibited either a neutral or low-efficacy agonist response at GABA α1 (96±7%), α2 (99±10%),
α3 (108±6%), and α4 (107±5%) receptors. However, a low-efficacy partial inverse agonist
response was observed at the α5 receptor (88±7% of the GABA response). Flumazenil exhibited
an efficacy profile that was qualitatively similar to βCCt at the α1 (99±5%), α3 (118±7%), and
α5 (96±6%) subtypes. At the α2 receptor, flumazenil produced a low-efficacy agonist response
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(115±4%), while βCCt was GABA neutral (99±10%). Flumazenil also produced a qualitatively
similar response to βCCt at the α4 receptor, albeit the magnitude of GABA potentiation by
flumazenil far exceeded that of βCCt (132±6 vs. 108±6%, respectively). However, it is
important to note, with regard to α4/α6β3γ2 subtypes, the agonist effect was observed at 10
μM, far above that required for agonist efficacy at the DS subtypes. In contrast, ZK 93426
produced a clear agonist profile, potentiating GABAergic activity by 137±8–148±11% across
the α1–α4 subtypes, but was GABA neutral at the α5 receptor (96±6%). These findings
suggested that βCCt had no appreciable intrinsic efficacy. The rationale for referring to this
agent as a “mixed agonist-antagonist” was based on the fact that, despite the ability to potentiate
GABA at certain receptor subtypes, it was “GABA neutral” at select doses. In addition, at
select doses, βCCt and 3-PβC were capable of competitive antagonism of classical
benzodiazepine agonists,60,64,72 therefore, the development of subtype-selective antagonists
for GABAA receptors, such as βCCt, which targeted the GABAA α1 receptor as a weak agonist-
like antagonist,74 should facilitate efforts to understand the antialcohol action of β-carbolines
in nonhuman primates and humans as well.
In the NIMH supported PDSP screen neither βCCT, 3PBC, nor WYS8 exhibited significant
interactions at other receptors (see http://pdsp.med.unc.edu for details).
Conclusion
Ethanol allosterically modulates the GABA receptor complex to open the chloride channel and
hyperpolarize cells. At the pharmacological level, the effects of ethanol can be antagonized
with GABA antagonists.109 Unfortunately, the paucity of high affinity subtype selective
ligands capable of discriminating among the various GABAA receptor subtypes has, thus far,
precluded study of the precise role GABAA subunits play in mediating EtOH-maintained
responding.
A series of β-carboline ligands described here has exhibited some selectivity at the α1 receptor
subtype which included β-carboline-3-carboxylate-t-butyl ester (βCCt, 1) and 3-propoxy-β-
carboline hydrochloride (3-PBC, 2). These ligands displayed a 20-fold and 10-fold selectivity,
respectively, for the α1 subtype over the α2 and α3 receptors, as well as over 150-fold selectivity
for the α1 site over the α5 subtype.2,3 βCCt (1) was more selective at the α1 subtype in vitro
than the classical α1 selective agonists zolpidem (3) and CL 218872 (4).60,98,99 βCCt and 3-
PBC are capable of competitive antagonism of classical benzodiazepine agonists,3,60,72
therefore, the development of subtype-selective antagonists for GABAA receptors which
targets the GABAA α1 receptor as a weak agonist-like antagonist,74 should facilitate efforts to
understand the antialcohol actions of β-carbolines in nonhuman and human primates alike.
Compared with Naltrexone, the reductions in alcohol responding were more selective and
longer in duration.107 The goal of the present study was to identify novel α1 GABAA subtype-
preferring ligands that may serve as prototypes for further evaluation of clinical efficacy. These
types of compounds may provide treatments for excessive alcohol drinking and the negative
affective states associated with abstinence. Ligands that enhance GABAergic tone may be
effective and safe treatments for both excessive alcohol drinking and the negative affective
states associated with abstinence. This may represent novel, new pharmacotherapies to treat
alcoholism.
Studies of the structure-activity relationships confirmed that occupation of region LDi of the
receptor pharmacophore model did enhance α1 selectivity in comparison to the affinity of the
non-selective ligands or the α5 selective ligands. Full occupation of the LDi lipophilic region
by β-carbolines may account for the potency/selectivity of this class of ligands at the α1 subunit.
Based on the SAR, the most potent α1 selective ligand was 6-substituted acetylenyl βCCt
(WYS8, 7). It was suggested the attenuation of EtOH-motivated responding effected by WYS8
Yin et al. Page 9













(7) was mediated via the α1 selective antagonism of the GABAA/.BzR receptor.2 In regard to
ester functions at C(3), although both (R) and (S) enantiomers exhibited approximately a 4-
fold selectivity for the α1β3γ2 subtype, the (R) isomer remained more potent in vitro at all 5
BzR sites. Two factors affected high affinity binding at BzR with respect to β-carbolines, one
of which was the lipophilicity of the substituent which interacted at L1. The second factor was
the ability of the substituent at position-3 to release electron density to the pyridine ring.
The most selective ligand for α1 subtypes, to date, to these authors’ knowledge was WYS8
(7). This 6-substituted acetylenyl βCCt (7) was 214 fold more selective for α1 isoforms over
α5 isoforms. WYS8 can clearly be differentiated from nonselective BDZs by its selective
binding affinity at the α1 receptor subunit and reduced capacity to potentiate GABA in
Xenopus oocytes.
Innate elevations of the α1 and α2 subunits of the HAD rat may contribute to the capacity of
novel β-carboline ligands to function as both anxiolytic agents and alcohol antagonists in this
genetic rat line.107 These differences may explain the capacity of these novel β-carboline
ligands to block alcohol drinking and still exhibit anxiolytic actions in the P and HAD alcoholic
rats. WYS8 may be a suitable ligand to evaluate as a preclinical agent to reduce alcohol
dependence. Its reduced efficacy at the α1 – 2 subunits in potentiating GABA may render it a
safe BDZ receptor ligand devoid of synergistic interactions with alcohol.
Experimental Section
Biological & Pharmacological Testing
Methods for in vitro receptor binding and efficacy in oocytes follow previous work.129, 130
Competition binding assays were performed in a total volume of 0.5 mL at 4 °C for 1 hour
using [3H] flunitrazepam as the radiolabel. For these binding assays, 20–50 μg of membrane
protein harvested with hypotonic buffer (50 mM Tris-acetate pH 7.4 at 4 degree) was incubated
with the radiolabel as previously described.119 Nonspecific binding was defined as
radioactivity bound in the presence of 100 μM diazepam and represented less than 20% of total
binding. Membranes were harvested with a Brandel cell harvester followed by three ice-cold
washes onto polyethyleneimine-pretreated (0.3%) Whatman GF/C filters. Filters were dried
overnight and then soaked in Ecoscint A liquid scintillation cocktail (National Diagnostics;
Atlanta, GA). Bound radioactivity was quantified by liquid scintillation counting. Membrane
protein concentrations were determined using an assay kit from Bio-Rad (Hercules, CA) with
bovine serum albumin as the standard.
The results are summarized in Tables 1–3.
The electrophysiological analyses of all selective compounds were performed with whole cell
variation of the patch-clamp-technique, in HEK cells employing GABA concentrations around
the subtype-specific EC203,120 to depict the quantitative efficacy difference [i.e., GABA
modulation] and qualitative subunit modulation [i.e., subunit type] of these ligands relative to
diazepam.
Melting points were taken on a Thomas-Hoover melting point apparatus or an Electrothermal
Model IA8100 digital melting point apparatus and are reported uncorrected. Proton NMR
spectra were recorded on a Bruker 250- or 300-MHz multiple-probe instrument. Infrared
spectra were recorded on a Nicolet DX FTIR BX V5.07 spectrometer or a Mattson Polaris
IR-10400 instrument. Low-resolution mass spectral data (EI/CI) were obtained on a Hewlett-
Packard 5985B GC-mass spectrometer, while high resolution mass spectral data were taken
on a VG autospectrometer (Double Focusing High Resolution GC/Mass Spectrometer, UK).
Microanalyses were performed on a CE Elantech EA1110 elemental analyzer. Analytical TLC
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plates employed were E. Merck Brinkman UV active silica gel (Kieselgel 60 F254) on plastic,
and silica gel 60b for flash chromatography was purchased from E. M. Laboratories. All
chemicals were purchased from Aldrich Chemical Co. unless otherwise stated. All solvents
were dried according to the published procedures.
1,2,3,4-Tetrahydro-9H-pyrido [3,4-b] indole-3-carboxylic acid (11)—D, L-
tryptophan (1000 g, 4.9 mol) was added to a solution of aq sodium hydroxide (12 L, 0.4 N)
after which the mixture was stirred until it dissolved. Formaldehyde (560 mL of a 37% aq
solution, 6.9 mol) was added and the solution was allowed to stir for three days at 37 °C. Glacial
acetic acid (400 mL) was added which resulted in the precipitation of a solid as a fine
suspension. The mixture was allowed to stir for two days, after which additional solid formed.
The solid was filtered from the medium, washed with water (4 × 1000 mL), and dried to give
11 (953g, 90.0%). 11: mp 295 °C (lit mp 293 °C)135 (lit mp 286 °C);136 (IR (KBr) 3600-2300,
1630 cm−1; MS (CI, CH4), m/z (relative intensity) 217 (M+ + 1, 50), 216(62), 169(59), 144
(100). This material was employed directly in the next step.
Ethyl 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylate (12)—The 1,2,3,4-
tetra-hydro-9H-pyrido[3,4-b]indole-3-carboxylic acid 11 (500 g, 2.3 mol) was dissolved in
anhydrous ethanol (9 L) in a 12L (3 neck) flask, and conc sulfuric acid (98%, 245 mL, 4.6 mol)
was carefully added to the solution until most of the solid dissolved. The reaction mixture was
heated to reflux under nitrogen until the starting material was no longer detected by TLC on
silica gel (48 h), and the solution became homogeneous. The reaction solution was cooled and
the solvent removed under reduced pressure. The residue was dissolved in H2O (6.4 L) and
the pH of the solution adjusted to 8 with cold aq NH4OH (conc.) after which a precipitate
formed. This mixture was then extracted with CHCl3 (6 × 2.5 L). The combined organic layers
were dried (Na2SO4) and the solvent was removed under reduced pressure to yield a light tan
solid which was dried in a vacuum oven at 100 °C to provide 12 (465 g, 83%). 11: mp 150 °
C (lit. mp 149–150 °C);90,137 1H (300 MHz, CDCl3) δ 1.33 (t, J = 7.32 Hz, 3H), 2.45 (s(br),
1H), 2.88 (dd, J = 9.70 Hz, J = 15.37 Hz, 1H), 3.13 (dd, J = 4.76 Hz, J = 15.5 Hz, 1H), 3.77
(dd, J = 4.76 Hz, J = 9.70 Hz, 1H), 4.07 (s(br), 2H), 4.26 (q, J = 7.14 Hz, 2H), 7.18-7.08 (m,
2H), 7.29 (d, J = 7.87 Hz, 1H), 7.48 (d, J = 7.68 Hz, 1H), 8.17 (s(br), 1H); MS (CI CH4) m/e
144 (97.3), 245 (M+1, 87), 244 (100), 183 (6), 171 (33), 144 (83). This material was employed
directly in the next step.
Ethyl 9H-pyrido[3,4-b]indole-3-carboxylate (8)—Into a round bottom flask (12 L)
equipped with a reflux condenser and an overhead stir was added 1,2,3,4-tetrahydro-β-
carboline-3-carboxylic acid ethyl ester 12 (200g, 0.86 mol) and dry benzene (8 L). The solution
was allowed to heat to reflux at which time activated MnO2 (200 g) was added to the flask.
Additional quantities of activated MnO2 were added until analysis by TLC (silica gel/ethyl
acetate) indicated the absence of starting material. The hot solution was filtered through a bed
of celite to remove the MnO2 and the filter cake was washed with hot benzene. The benzene
layers were allowed to cool. A precipitate formed and was collected by vacuum filtration, which
provided (100–120g, 50%–60%) of pure β-carboline-3-carboxylic acid ethyl ester 8 (βCCE).
The benzene which remained in the filtrate was removed under reduced pressure to provide
25–35 g of additional βCCE, but as crude material. The crude material could be purified by
recrystalization from ethanol. 8: mp 225–227 °C (lit. 224–229 °C);137,138 1H (300 MHz,
DMSO-d6) δ 1.36 (t, J = 6.95 Hz, 3H), 4.37 (q, J = 6.95 Hz, 2H), 7.37-7.24 (m, 1H), 7.68-7.57
(m, 2H), 8.38 (d, J = 7.87 Hz, 1H), 8.90 (s, 1H), 8.97 (s, 1H), 10.7 (br, 1H); MS (CI, CH4) m/
e 241 (M+ + 1, 47), 195 (22), 168 (100), 140 (9). This material was employed directly in the
next step.
Yin et al. Page 11













β-Carboline-3-carboxylic acid (9)—β-Carboline-3-carboxylic acid ethyl ester 8 (30.0 g,
0.126 mol) was suspended in aq NaOH (10%, 1.5L) and heated to reflux until all the material
had gone into solution (1 h). The heating was continued for an additional 3 h. The reaction
mixture was cooled to rt and acidified by addition of ice cold aq conc HCl to pH 4. The
precipitate which resulted was stirred overnight. The solid was collected by vacuum filtration
and washed with H2O (2 × 150 mL). The product was dried at 80 °C under vacuum for 24 h
to provide 9 (26.1 g, 99%). 9: mp 220–221 °C (lit. mp 220 °C);67 IR (KBr) 3260, 2970, 1710
cm−1; 1H NMR (CDCl3) δ 7.31 (t, J = 7.32 Hz, 1H), 7.69-7.57 (m, 2H), 8.38 (d, J = 7.87 Hz,
1H), 8.90 (s, 1H), 8.96 (s, 1H), 12.10 (s, 1H); MS (CI, CH4), m/e (M+ + 1, 269). Anal. Calcd.
for C16H16N2O2 (0.55 H2O): C, 69.07; H, 6.19; N, 10.07. Found: C, 68.81; H, 5.77; N, 10.00.
β-Carboline-3-carboxylic acid t-butyl ester (1)—To a solution of carbonyl diimidazole
(28.2 g, 0.177 mol) in anhydrous DMF (1.2 L) was added dry β-carboline-3-carboxylic acid
9 (25 g, 0.118 mol) under argon. The reaction mixture was initially a pale yellow-colored
suspension, but after stirring for 30 min, a purple or red-colored solution resulted. The reaction
mixture was stirred for an additional 2h at rt and carbon dioxide was released during the
reaction. Analysis by TLC (silica gel) indicated the absence of starting material on the baseline.
To this reaction mixture was added dry DBU (18 g, 0.118 mol) and dry freshly distilled t-butyl
alcohol (437 g/560 mL, 50 eq). The mixture was heated at 85°C for 18h until analysis by TLC
indicated the disappearance of the imidazole intermediate. The solvent was then removed under
reduced pressure. The residue was partitioned between CH2Cl2 (1.2 L) and H2O (800 mL).
The organic layer was separated and the H2O layer was extracted with CH2Cl2 (2 × 500 mL).
The combined organic layer was washed with an aq solution of 10% K2CO3, water, brine and
dried (Na2SO4). The solvent was removed under reduced pressure and the residue was purified
by flash chromatography (silica gel, EtOAc/hexane = 1:1) to provide βCCt (20 g, 65%) as a
white solid. βCCt can be recrystallized from EtOAc to provide white crystals 1: mp 301–303°
C (lit. mp 298–300);80 IR (KBr) 3500-3400, 3200-3000, 1610, 1560, 1370, 1340 cm−1; 1H
(300 MHz, DMSO-d6) δ 1.74 (s, 9H), 7.37 (t, J = 7.48 Hz, 1H), 7.63 (t, J = 7.66 Hz, 1H), 7.73
(d, J = 8.52 Hz, 1H), 8.24 (d, J = 7.89 Hz, 1H), 8.85 (s, 1H), 9.12 (s, 1H), 8.97 (s, 1H), 10.19
(br, 1H); The spectral data for 1 were identical to those reported in the literature.88
2,2,2-Trifluoroethyl β-carboline-3-carboxylate 15 was prepared from β-carboline-3-carbo-
xylic acid 9 and 2,2,2-trifluoroethyl alcohol following the procedure employed for the
preparation of 1. 15: mp 264–266 °C; IR (NaCl) 3275, 1735 cm−1; 1 H NMR (300 MHz,
CDCl3) 4.87 (m, 2H), 7.42 (m, 1H), 7.65 (m, 2H), 8.24 (d, J = 7.9 Hz, 1H), 8.93 (s, 1H), 9.09
(s, 1H), 9.10 (s, br, 1H);; 13C NMR (75.5 MHz, CDCl3) δ 60.4, 60.8, 112.8, 118.9, 120.7,
121.2, 122.7, 127.8, 129.2, 134.5, 135.2, 138.1, 141.3, 164.5; MS (EI) m/e (relative intensity)
294(M+, 30), 195(7), 168(100), 167(42). Anal. Calcd. for C14H9F3N2O2: C, 57.15; H, 3.08;
N, 9.52. Found: C, 57.22; H, 3.14; N, 9.23.
9H-β-Carboline-3-carboxylic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester 16 was
prepared following the procedure employed for the preparation of 1. 16: 1H NMR (300 MHz,
DMSO-d6) δ 7.05–7.21 (m, 1H), 7.33–7.44 (t, 1H), 7.61–7.72 (m, 2H), 8.48 (d, J = 7.89 Hz,
1H), 9.09 (s, 2H), 12.31 (s, 1H); 13C NMR (75.5 MHz, DMSO-d6) δ 65.9, 66.8, 112.9, 120.1,
120.9, 122.8, 127.8, 129.4, 133.3, 134.9, 138.4, 141.3, 162.9. This material was pure by TLC
(silica gel).
9H-β-Carboline-3-carboxylic acid 2,2,2-trichloro-ethyl ester 17 was prepared following the
procedure employed for the preparation of 1. 17: 1H NMR (300 MHz, CDCl3) δ 5.17 (s, 2H),
7.38–7.44 (m, 1H), 7.63–7.74 (m, 2H), 8.27 (d, J = 7.95 Hz, 1H), 8.95 (s, 1H), 9.21 (s, 1H),
9.66 (s, 1H). This material was pure by TLC (silica gel).
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9H-β-Carboline-3-carboxylic acid 2,2,2-trifluoro-1-methyl-ethyl ester 18 was prepared
following the procedure employed for the preparation of 1. 18: m.p. 247 249 °C; IR (NaCl)
2359, 1729, 1345, 1251, 1092, 729, 450 cm−1; 1H NMR (300 MHz, CDCl3) δ 1.82 (d, J = 6.1
Hz, 3H), 5.96 (q, 1H), 7.42 (t, 1H), 7.67 (m, 2H), 8.26 (d, J = 7.6 Hz, 1H), 8.8 (s, 1H), 8.9 (s,
1H), 9.5 (br, s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 16.5, 79.1, 112.3, 118.5,121.2, 121.5,
121.9, 128.8, 129.2, 133.9, 137.4. This material was pure by TLC (silica gel).
(S)-1,1,1-Trifluoroisopropyl β-carboline-3-carboxylate (21)—To a solution of
carbonyl diimidazole (0.168 g, 1.03 mmol) in anhydrous DMF (5 mL), β-carboline-3-
carboxylic acid 9 (0.10 g, 0.47 mmol) was added. The reaction mixture which resulted was
stirred for 2 h at rt until analysis by TLC (silica gel) indicated the absence of starting material
on the baseline. The solution which resulted was then cooled to −6 °C and this was followed
by addition of (S)-1,1,1-trifluoropropan-2-ol (2.3 eq) which was contaminated with some
EtOH. The dry DBU (100 mg, 0.68 mmol) in dry DMF (0.5 mL) was slowly syringed into the
reaction mixture at −6 °C. The mixture was stirred at 0 °C for 8 h until analysis by TLC (silica
gel) indicated the diaspperance of the imidazole intermediate. The reaction mixture was then
poured into ice water (30 mL) and extracted with CH2Cl2 (3 × 40 mL). The combined organic
layers were washed with H2O (5 × 40 mL), brine and dried (Na2SO4). The solvent was removed
under reduced pressure and the residue was purified by flash chromatography (silica gel,
EtOAc/hexanes = 2:1) to provide 21 (0.113 g, 78%) as a white solid. 21: mp 239–241 °C;
 (c = 0.81, in CHCl3); IR (NaCl) 3266, 1725, 1502 cm−1; 1H NMR (300 MHz,
CDCl3) δ 1.63 (d, J = 6.6 Hz, 3H), 5.75 (m, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.64 (t, J = 7.6 Hz,
1H), 7.72 (d, J = 8.1 Hz, 1H), 8.25 (d, J = 7.9 Hz, 1H), 8.91 (s, 1H), 9.18 (s, 1H), 10.04 (s, br,
1H); MS (EI) m/e (relative intensity) 308 (M+, 17), 168 (100), 140 (21). Exact mass calcd. for
C15H11F3N2O2: 308.0773. Found: 308.0773. Anal. Calcd. for C15H11F3N2O2: C, 58.45;H,
3.60; N, 9.09. Found: C, 58.15; H, 3.63; N, 8.88.
(S)-1,1,1-Trifluorobutan-2-ol was prepared following the literature procedure.114 To an
oven-dried, 25 mL round-bottom flask was transferred (−)-DIP-Chloride (10.68 g, 33 mmol)
in a glove box. Then 1,1,1-trifluorobutan-2-one (4.03 g, 32 mmol) was added at rt under argon.
The reaction mixture was stirred at rt for 10 h. Ethyl ether was added and the reaction solution
was cooled to 0 °C followed by addition of acetaldehyde (1.6 g, 1.1 eq). The reaction mixture
was allowed to warm to rt and stirring was continued for 24 h while the second equivalent of
α-pinene was liberated. An aq solution of sodium hydroxide (2.5M, 30 mL) was added and the
solution which resulted was extracted with ether (3 × 30 mL). The ether layer was dried
(Na2SO4) and fractionally distilled through a Pyrex distilling column packed with glass beads.
The desired alcohol was collected along with EtOH (20%). (S)-1,1,1-Trifluorobutan-2-
ol: 1H NMR (300 MHz, CDCl3) 1.04 (dt, J = 0.6 Hz and J = 7.4 Hz, 3H), 1.58 (m, 1H), 1.72
(m, 1H), 3.82 (m, 1H). This material was used in a later step without further purification.
(R)-1,1,1-Trifluoroisopropyl β-carboline-3-carboxylate 22 was prepared from the acid 9
and (R)-1,1,1-trifluoropropan-2-ol following the procedure employed for preparation of
(S)-1,1,1-trifluoro-propan-2-ol. 22: mp 239–241 °C;  (c = 0.88, in CHCl3); The
spectral data for 22 were identical to those for 21; however, the optical rotation was in the
opposite direction.
(S)-β-Carboline-3-carboxylic acid sec-butyl ester (23)—To a solution of carbonyl
diimidazole (1.53 g, 9.4 mmol) in anhydrous DMF (50 mL) was added β-carboline-3-
carboxylic acid 9 (1.0 g, 4.7 mmol). The reaction mixture was stirred for 2 h at rt and carbon
dioxide was released during the reaction. Analysis by TLC (silica gel) indicated the absence
of starting material on the baseline. To this reaction mixture was added dry DBU (0.72 g, 4.7
mmol) and dry (S)-butyl alcohol (1.13 g, 15.2 mmol). The mixture which resulted was heated
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at 55 °C for 8 h until analysis by TLC (silica gel) indicated the disappearance of the imidazole
intermediate. The solvent was then removed under reduced pressure. The residue was
partitioned between CH2Cl2 (100 mL) and H2O (100 mL). The organic layer was separated
and the H2O layer was extracted with CH2Cl2 (2 × 80 mL). The combined organic layer was
washed with H2O (3 × 100 mL), brine and dried (Na2SO4). The solvent was removed under
reduced pressure and the residue was purified by flash chromatography (silica gel, EtOAc/
hexane = 2:1) to provide 23 (0.96 g, 76%) as a white solid. 23: mp 212–213 °C; [α]25 = 35.6°
(CHCl3, c = 1.43); IR (KBr) 3222, 1706, 1622, 1494 cm−1; 1 H NMR (300 MHz, CDCl3) δ
0.99 (t, J = 7.5 Hz, 3H), 1.40 (d, J = 6.3 Hz, 3H), 1.79 (m, 2H), 5.27 (m, 1H), 7.34 (t, J = 7.9
Hz, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 7.9 Hz, 1H), 8.44 (s,
1H), 9.10 (s, 1H), 11.47 (s, br, 1H); MS (CI, CH4) m/e (relative intensity) 269 (M+ + 1, 100),
241(15), 213(41), 195(14). Anal. Calcd. for C16H16N2O2: C, 71.62; H, 6.01; N, 10.44. Found:
C, 71.33; H, 6.09; N, 10.26.
(R)-β-Carboline-3-carboxylic acid sec-butyl ester 24 was prepared in 75% yield following
the procedure for preparation of 1. 24: [α]25 = -35.2° (CHCl3, c = 1.25) The spectral data for
22 were identical to those for 23, except the optical rotation was opposite in direction.
6-Iodo-9H-β-carboline-3-carboxylic acid t-butyl ester (5)—Into a round bottom flask
(250 mL) was added CF3CO2Ag (1.03 g, 4.67 mmol), β-carboline-3-carboxylic acid t-butyl
ester 9 (1.02 g, 3.83 mmol), and CHCl3 (100 mL). This was followed by addition of iodine
(1.15 g, 4.66 mmol). The reaction mixture was allowed to stir at rt for 6 h after which another
portion of CF3CO2Ag (500 mg, 2.26 mmol) was added and stirring continued for another 10
h at reflux. Analysis by TLC (silica gel) indicated that most of the βCCt had disappeared. The
reaction mixture was filtered through a bed of celite to remove the solid salts and the filter cake
was washed with EtOH (3 × 50 mL). The solvent was removed under reduced pressure and
the residue was purified by flash chromatography (silica gel, EtOAc/hexane = 4:1) to provide
5 (908 mg, 65%) as a white solid. 5: mp 347–348 °C (dec.); IR (NaCl) 3223, 1710, 1485, 1323,
1245, 1161, 1104, 1020 cm−1; 1 H NMR (300 MHz, CDCl3) δ 1.68 (s, 9H), 7.63 (d, J =8.6 Hz,
1H), 7.85 (dd, J = 1.5 Hz and J = 8.6 Hz, 1H), 8.12 (s, 1H), 8.53 (d, J = 1.4 Hz, 1H), 9.31 (s,
1H), 11.47 (s, br, 1H); 13C NMR (75.7 MHz, CDCl3) δ 28.3, 80.8, 83.6, 115.1, 118.1, 123.9,
126.7, 131.2, 134.1, 136.8, 137.5, 138.7, 140.4, 164.9; MS(EI800) m/e (relative intensity) 395
(M+ + 1, 18), 367 (20), 339 (100), 268 (33). Anal. Calcd. for C16H15IN2O2: C, 48.75; H, 3.84;
N, 7.11. Found: C, 49.01; H, 3.91; N, 6.95.
6-Trimethylsilanylethynyl-9H-β-carboline-3-carboxylic acid t-butyl ester (6)—
Into a round bottom flask (50 mL) which contained a solution of degassed THF/Et3N (10 mL/
2 mL), was added 6-iodo-9H-β-carboline-3-carboxylic acid t-butyl ester 5 (400 mg, 1.02
mmol), bis[triphenylphosphine] palladium dichloride (35 mg, 5 mol%) and copper(I) iodide
(7 mg, 5 mol%) Note: Practically, on a small scale, CuI could be used up to 10–15 mol%
because of its lower molecular weight compared to the palladium catalyst; on a bigger scale,
both Pd(PPh3)2Cl2 and CuI can be used as low as 0.5–1 mol%. The reaction mixture was then
degassed 2 times with an oil pump at −78 °C, and then the trimethylsilyl acetylene (300 mg,
3.06 mmol) was added into the mixture and it was degassed one more time at −78 °C. The
reaction mixture was gradually allowed to warm to rt and stirred at rt for an additional 0.5–1h
until all the starting material had disappeared (TLC analysis indicated that the original red spot
changed color to purple, since both s.m. and product had very similar Rf values). The solvent
was removed under reduced pressure at this point and the residue was purified by flash
chromatography (silica gel, EtOAc/hexane = 4:1) to provide 6 (340 mg, 92%) as a white
solid. 1H NMR (300 MHz, CDCl3) δ 1.71 (s, 9H), 1.75 (s, 9H), 7.67 (m, 2H), 8.26 (d, J = 7.6
Hz, 1H), 8.8 (s, 1H), 8.9 (s, 1H), 9.5 (br, 1H); 13C NMR (75.5 MHz, CDCl3) δ 0.021, 28.3,
81.9, 92.6, 105.7, 113.2, 114.9, 117.7, 121.3, 125.5, 128.3, 132.4, 133.8, 138.2, 138.4, 141.5,
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165.4; EIMS 364(M+, 38), 293(12), 264(100), 249(48), 124(60). This material was employed
directly in the next step.
6-Ethynl-9H-β-carboline-3-carboxylic acid t-butyl ester (7)-WYS8—To a solution
of 6-trimethyl-silanyl-β-carboline-3-carboxylic acid t-butyl ester 6 (850 mg, 2.32 mmol) in
THF (10 mL) was added 1.2 eq of TBAF (2.8 mL of 1M TBAF/THF solution) at 0 °C and then
the solution was allowed to warm to rt. After consumption of the starting material as indicated
by TLC, H2O (10 mL) was added and the mixture was extracted with CH2Cl2 (3 × 20 mL).
The combined organic layer was concentrated under reduced pressure and the residue was
chromatographed on a short silica gel column (EtOAc/hexane = 4:1) to give 7 (620 mg, 92%)
as a white solid. 7: 1H NMR (300 MHz, CDCl3) δ 1.75 (s, 9H), 3.54 (s, 1H), 7.62–7.85 (m,
2H), 8.41 (s, 1H), 8.83 (s, 1H), 9.33 (s, 1H), 11.1 (s, 1H); EIMS 292 (M+, 25), 236(12), 192
(100), 164(30). This material was pure by TLC (silica gel) and used directly in a later step.
6-Thiophen-2-yl-9H-β-carboline-3-carboxylic acid t-butyl ester (30a).
Representative procedure for preparation of 6-subsitituted β-carbolines—A
solution of 6-Iodo-β-carboline-3-carboxylic acid t-butyl ester 5 (265 mg, 0.67 mmol) in dry
toluene (15 mL) was degassed under vacuum and purged with dry N2 through the solution 3
times. The mixture was then heated to 140 °C under nitrogen after which tetrakis
(triphenylphosphine) palladium (0) (77 mg, 0.067 mmol, 10mol%) and 2-(tributylstannyl)
thiophene (718 mg, 2.01 mmol) were added in one portion. The mixture was heated to reflux
under nitrogen. After 12 h, the mixture was allowed to cool to rt and the precipitate which
resulted was removed by vacuum filtration. The filtrate was concentrated under reduced
pressure and the residue was treated with a saturated aq solution of NaHCO3 (30 mL) and
extracted with CH2Cl2 (3 × 25 mL). The combined extracts were washed with brine and dried
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified by
flash chromatography (silica gel, EtOAc/hexane = 5:1) to provide a white solid 30a (195 mg,
83%). 30a: 1H NMR (300 MHz, CDCl3) δ 2.07 (s, 9H), 7.15 (t, 1H), 7.31 (d, J = 3Hz, 1H),
7.40 (d, J = 3Hz, 1H), 7.89 (q, 2H), 8.44 (s, 1H), 8.89 (s, 1H), 9.32 (s, 1H), 11.2 (s, 1H). This
material was pure by TLC (silica gel).
6-Furan-2-yl-9H-β-carboline-3-carboxylic acid t-butyl ester 29a was prepared following
the procedure for preparation of 30a. 29a: 1H NMR (300 MHz, CDCl3) δ 1.63(s, 9H), 6.63
(m, 1H), 6.97 (d, J = 6Hz, 1H), 7.70 (d, J = 9Hz, 1H), 7.77 (s, 1H), 7.96 (d, J = 9Hz, 1H), 8.73
(s, 1H), 8.90 (s, 1H), 8.96 (s, 1H), 12.1 (s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 28.4, 80.7,
102.3, 106.3, 112.4, 113.2, 117.4, 117.8, 127.1, 127.8, 133.6, 134.1, 138, 140.6, 142.6, 154.1,
165.0, 166.0. This material was pure by TLC (silica gel).
6-Furan-2-yl-9H-β-carboline-3-carboxylic acid 2,2,2-trifluoro-ethyl ester 29b was
prepared following the procedure for preparation of 30a. 29b: 1H NMR (250 MHz, CDCl3) δ
4.82–4.92 (m, 2H), 6.54 (s, 1H), 6.75 (s 1H), 7.38 (s, 1H), 7.65 (d, J = 10Hz, 1H), 7.96 (d, J
= 10Hz, 1H), 8.5 (s, 1H), 8.93 (s, 1H), 9.13 (s, 1H), 9.59 (s, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 60.9, 105.3, 112.5, 112.8, 113.3, 117.6, 119.2, 122.3, 123.8, 125.3, 127.9, 134.7,
135.3, 138.6, 140.6, 142.7, 154.1, 164.4. This material was pure by TLC (silica gel).
6-Iodo-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester (35)—To a solution of
6-iodo-β-carboline-3-carboxylic acid t-butyl ester 5 (2 g, 5.06 mmol) in anhydrous CH2Cl2
(30mL), (Boc)2O (1.32 g, 6.07 mmol) and DMAP(123 mg, 1.01 mmol) were added. The
reaction mixture was allowed to stir at rt for half an hour until analysis by TLC (silica gel)
indicated that the starting material had been converted into the Boc protected indole 35. The
solvent was removed under reduced pressure and the residue was purified by flash
chromatography (silica gel, EtOAc/hexane = 5:95) to provide 35 (2.3 g, 92%) as a white solid.
35: mp 317–320 °C; IR (NaCl) 2975, 2917, 1728, 1457, 1343, 1238, 1154, 1119, 1031,
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811cm−1; 1H NMR (300 MHz, CDCl3) δ 1.71 (s, 9H), 1.77 (s, 9H), 7.91 (d, J = 8.972 Hz, 1H),
8.22 (d, J = 8.972Hz, 1H), 8.42 (s, 1H), 8.61 (s, 1H), 9.61 (s, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 28.1, 28.2, 82.1, 85.8, 87.2, 115.9, 118.5, 125.7, 129.9, 130.6, 135.7, 138.9, 143.0
149.6 164.1; MS (EI) m/e (relative intensity) 494 (M+, 42), 438 (71), 338 (100), 294 (70), 268
(8), 212 (8), 168 (35). Anal. calcd. for C21H23IN2O4(0.1 C6H14): C, 51.60; H, 4.85; N, 5.57;
Found: C, 51.84; H, 4.88; N: 5.45.
6-Trimethylsilanylethynyl-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester
(36)—Dichlorobis(triphenylphosphine)palladium(II) (140 mg; 2 mol %), and CuI (40 mg; 2
mol %) were added to a solution of 6-iodo-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester
35 (4.9 g; 10 mmol) in anhydrous THF (30 mL) and triethylamine (10 mL). The mixture was
degassed, and back-filled three times with argon. Then trimethylsilyl acetylene (1.08 g; 11
mmol) was added with stirring under argon. After the mixture was allowed to stir for 1 h, the
solvents were removed under vacuum and the residue was chromatographed on a short column
(silica gel, hexane/CH2Cl2 = 7:3) to give 36 (4.36 g, 94%) as a white solid. 36: mp 334–336
°C (dec); IR (NaCl) 2974, 2137, 1732, 1559, 1476, 1469, 1368, 1343, 1309, 1247, 1156, 1109,
872, 842, 760 cm−1; 1H NMR (300 MHz, CDCl3) δ 0.31 (s, 9H), 1.71 (s, 9H), 1.78 (s, 9H),
7.77 (d, J = 8.97 Hz, 2H), 8.25 (s, 1H), 8.41 (d, J = 8.61 Hz, 2H), 8.65 (s, 1H), 9.62 (s,
1H); 13C NMR (75 MHz, CDCl3) δ 0.11, 28.1, 28.2, 82.1, 85.8, 94.4, 104.4, 116, 116.5, 118.7,
123.5, 124.7, 131.6, 133.7, 136.2, 138.1, 139.2, 142.9, 149.7, 164.1; MS (EI) m/e (relative
intensity) 465 (M+, 30), 409 (100), 365 (21), 308 (80), 262 (25), 249 (40). This material was
pure by TLC (silica gel) and used in the next step.
6-Ethynyl-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester 34—To a solution of
6-trimethylsilanylethynyl-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester 36 (2.14g, 4.6
mmol) in THF (20 mL), 1.2 eq of TBAF (5.52 ml of 1M TBAF/THF solution) at 0 °C was
added and then the solution was allowed to warm to rt. After consumption of the starting
material as indicated by TLC (silica gel), H2O (10 mL) was added and the mixture was extracted
with CH2Cl2 (20 mL, 3X). The combined organic layer was concentrated under reduced
pressure and the residue was chromatographed on a short column (silica gel, hexane/CH2Cl2
= 4:1) to give 34 (1.66 g, 92%) as a white solid. 34: mp 226–229 °C; IR (NaCl) 3303, 2978,
2346, 2232, 1734, 1622, 1560, 1463 cm−1; 1H NMR (300 MHz, CDCl3) δ 1.54 (s, 9H), 1.72
(s, 9H), 1.79 (s, 9H), 3.17 (s, 1H), 7.79 (d, J = 8.76 Hz, 2H), 8.27 (s, 1H), 8.44 (d, J = 8.94 Hz,
2H), 8.67 (s, 1H), 9.64 (s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 27.3, 28.1, 28.2, 67.8, 82.1,
83.0, 85.1, 85.5, 116.0, 116.7, 123.5, 124.9, 133.7, 136.2, 138.1, 139.4, 143.0, 164.2; MS (EI)
m/e (relative intensity) 393 (M+, 32), 338 (13), 321 (26), 293 (100), 167 (28), 139 (24). Anal.
Calcd. for C23H24N2O4 (0.05 CH2Cl2): C, 69.78; H, 6.12; N, 7.06; Found: C: 69.70; H: 6.10;
N: 6.81.
1,2-Bis(9H-β-carboline-3-carboxylic acid tert-butyl ester) ethyne (32)—
Dichlorobis (tri-phenylphosphine)palladium(II) (60 mg, 2 mol%) and copper iodide (16 mg,
2 mol%) were added to a mixture of 6-ethynyl-β-carboline-3,9-dicarboxylic acid di-tert-butyl
ester 34 (1.6g, 4.1mmol) and 6-iodo-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester 35
(2.1g, 4.25mmol) in THF/TEA(30 mL; 4:1). The reaction mixture which resulted was
degassed, and back-filled three times with argon. The reaction mixture was then allowed to
stir at rt for about 1h until analysis by TLC (silica gel) indicated the starting materials were
absent. The solution was concentrated under reduced pressure and the residue was
chromatographed on a silica gel column with CH2Cl2 as the eluent to give 1,2-bis(β-
carboline-3,9-dicarboxylic acid di-tert-butyl ester) ethyne (2.97 g, 95%) as a white solid: mp
305–307°C; IR (NaCl) 2972, 2929, 1737, 1559, 1466, 1338, 1156, 1102, 823, 624cm−1; 1H
NMR (300 MHz, CDCl3) δ 1.72 (s, 9H), 1.79 (s, 9H), 7.86 (d, J = 8.97 Hz, 1H), 8.32 (s, 1H),
8.47 (d, J = 8.79Hz, 1H), 8.68 (s, 1H), 9.63 (s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 28.2, 82.1,
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85.8, 89.0, 116.0, 116.7, 118.6, 123.6, 124.3, 131.5, 133.3, 136.1, 138.1, 139.1, 143.0, 149.7,
164.2; MS (FAB) 759((M + H)+, 13). Anal. calcd. for C44H46N4O8 (H2O): C, 68.03; H, 6.22;
N, 7.21; Found: C: 68.10; H: 6.22; N: 7.21.
The 1,2-bis(β-carboline-3,9-dicarboxylic acid di-tert-butyl ester) ethyne 32 (800mg, 1.05
mmol) was added to a distilled solution of cumene (40 mL), which had been degassed. The
reaction vessel was evacuated and refilled with nitrogen three times. The temperature was then
brought to reflux for about 30 min until a yellow precipitate had formed. The mixture which
resulted was filtered and washed with hexane to give pure dimer 32 (545 mg, 93%). 32: m.p.
>350 °C (dec.); IR (KBr) 3227, 1716, 1327, 1162, 738, 450 cm−1; 1H NMR (300 MHz, DMSO)
δ 1.62 (s, 9H), 7.70–7.80 (m, 2H), 8.7 (s, 1H), 8.94 (s, 1H), 8.99 (s, 1H), 12.25 (s,1H); 13C
NMR (300MHz, CDCl3) δ 28.3, 80.8, 113.3, 114.6, 117.9, 125.8, 127.5, 131.9, 134.2, 138.0,
140.8, 164.9; MS (FAB) 559 ((M +H)+, 41). This material was pure by TLC (silica gel).
1,4-bis(9H-β-carboline-3-carboxylic acid tert-butyl ester) buta-1,3-diyne (33)—In
a round bottom flask (200 mL), PdCl2(PPh3)2 (58 mg, 2 mol%), CuI (16mg, 2 mol%), and N,
N-diisopropyl-ethylamine (534 mg, 4.92 mmol) were added and the mixture stirred under
argon. The flask was evacuated (degassed) and refilled with argon. The THF (40 mL) and 6-
ethynyl-β-carboline-3,9-dicarboxylic acid di-tert-butyl ester 34 (1.6 g, 4.1 mmol) were then
added (under argon) to the above mixture. To this flask methyl bromoacetate (410 mg, 2.5
mmol) was added, and the reaction mixture was stirred at rt for 6–8 h. The progress of this
reaction was monitored by TLC on silica gel. After the reaction was complete, 8–10 g of silica
gel was added and the solvent was removed under vacuum. The solid residue (a plug) was then
placed on a column and subjected to column chromatography (CH2Cl2) to give 1,4-bis(β-
carboline-3,9-dicarboxylic acid di-tert-butyl ester) buta-1,3-diyne (2.08 g, 65%): 1H NMR
(300 MHz, CDCl3) δ 1.74 (s, 9H), 1.81 (s, 9H), 7.82 (d, J = 8.79 Hz, 1H), 8.34 (s, 1H), 8.48
(d, J = 8.79 Hz, 1H), 8.69 (s, 1H), 9.65 (s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 28.2, 74.0,
81.2, 82.2, 86.0, 116.1, 116.9, 117.2, 123.7, 125.5, 131.3, 134.0, 136.2, 138.1, 139.6, 143.2,
149.6, 164.1; MS (FAB) 783((M + H)+, 100).
The 1,4-Bis-(β-carboline-3,9-dicarboxylic acid di-tert-butyl ester) buta-1,3-diyne (411 mg, 0.5
mmol) was added to a distilled solution of cumene (20 mL), which had been degassed. The
reaction mixture was evacuated and refilled with nitrogen three times. The temperature was
then brought to reflux for about 30 min until a yellow precipitate had formed. The mixture was
filtered and the solids washed with hexane to give pure dimer 33. 33: mp >350 °C (dec.) IR
(KBr) 3424, 1708, 1627, 1466, 1369, 1302, 1251, 1154, 1107, 1025, 846, 645 cm−1; 1H NMR
(300 MHz, DMSO) δ 1.63(s, 9H), 7.60–7.69(m, 2H), 8.40(s, 1H), 8.96(s, 1H), 9.04(s, 1H),
12.5(s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 28.3, 78.8, 82.5, 112.9, 118.1, 121.0, 122.1, 129.5,
131.5, 134.8, 141.1, 163.0, 131.9, 134.2, 138.0, 140.8, 164.9; MS (FAB) 583(M+, 100). This
material was pure by TLC (silica gel).
The synthesis of the ligands in Table 2b had been reported previously in reference 89.
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In vitro binding affinities of a series of α1 selective ligands (Ki in nM).
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Efficacy of βCCt in modulating GABA at recombinant GABAα1-α5 receptors2 in Xenopus
oocytes: comparison with other BzR antagonists.
Modulation of GABAA α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, and α5β3γ2 receptor subunit
combinations expressed in Xenopus oocytes by βCCt (open bars), flumazenil (shaded bars),
and ZK 93426 (black bars). A saturating concentration (1–10 μM) was coapplied over voltage-
clamped oocytes along with an EC50 of GABA.
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Orthogonal views of CoMFA contour maps for the affinity of 6-benzyl-substituted β-carbolines
at the α1β3γ2 BzR.
Orthogonal view of CoMFA contour maps for the α1β3γ2 receptor subtype with 6-benzyl-
substituted β-carbolines modeled by Huang.60 Green contours represent areas of positive steric
interaction at a contribution level of 85%, which would result in reduced binding affinity. Blue
contours represent areas of positive charge interaction at a level of 85%, which would increase
the affinity of a ligand.
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Alignment of bivalent ligands 32 and 33 within the included volume of the α1β3γ2 subtype.
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Large scale synthesis of βCCt and synthesis of 3PBC.
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CDI-mediated esterification of 3-substituted β-carbolines followed by the conversion into 3,6-
disubstituted β-carbolines.
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Preparation of 6-substituted acetylenyl βCCt (7, WYS8) and related bivalent ligands.
Yin et al. Page 33




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Bioorg Med Chem. Author manuscript; available in PMC 2011 November 1.
